节点文献

以α7 nAChR为靶点的药物研究进展

Advances on α7 nAChR as targets for drug development

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 谢冰雪张桂森张亮仁

【Author】 XIE Bing-xue;ZHANG Gui-sen;ZHANG Liang-ren;Peking University Health Science Center,State Key Laboratory of Natural and Biomimetic Drugs;Nhwa Institute of Pharmaceutical Research;

【机构】 北京大学药学院天然药物及仿生药物国家重点实验室江苏恩华药物研究院

【摘要】 α7 nAChR属于烟碱型乙酰胆碱受体,是由5个α7单体组成的配体门控离子通道。α7 nAChR的配体结合位点主要有两种,即激动剂(拮抗剂)结合位点以及变构调节位点。α7 nAChR是精神分裂症认知障碍以及阿尔茨海默病药物研究的一个重要靶点,现已有多个治疗药物处在临床试验阶段。本文主要综述了α7 nAChR激动剂以及变构调节剂药物的研究进展。

【Abstract】 α7 nAChR belongs to nicotinic acetylcholine receptor. α7 nAChR is a ligand-gated ion channels which consists of five α7 subunits. A variety of chemotypes could modulate α7 nAChR through interaction at distinct sites on the protein including orthosteric binding sites and PAM binding sites. It has been proved thatα7 nAChR is closely associated with schizophrenia and Alzheimer’s. Several drugs have been in clinical trials. In recent years,various types of novel molecules have been designed and synthesized,which are expected to become a newclass of drugs for schizophrenia and Alzheimer’s.

【关键词】 α7 nAChR激动剂变构调节剂
【Key words】 α7 nAChRagonistpositive allosteric modulators(PAMs)
【基金】 国家自然科学基金项目(81373272)
  • 【文献出处】 中国药物化学杂志 ,Chinese Journal of Medicinal Chemistry , 编辑部邮箱 ,2015年04期
  • 【分类号】R96
  • 【被引频次】13
  • 【下载频次】662
节点文献中: 

本文链接的文献网络图示:

本文的引文网络